What is Erste Group Bank’s Forecast for JNJ FY2027 Earnings?

Johnson & Johnson (NYSE:JNJ) – Analysts at Erste Group Bank boosted their FY2027 earnings estimates for Johnson & Johnson in a report issued on Tuesday, May 5th. Erste Group Bank analyst H. Engel now expects that the company will earn $12.66 per share for the year, up from their prior forecast of $12.63. The consensus estimate for Johnson & Johnson’s current full-year earnings is $11.57 per share.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. During the same period last year, the firm posted $2.77 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS.

Other equities analysts have also issued reports about the stock. Royal Bank Of Canada reiterated an “outperform” rating and issued a $265.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Argus lifted their price target on Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. The Goldman Sachs Group lifted their target price on Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Bank of America raised their target price on shares of Johnson & Johnson from $253.00 to $254.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Finally, Barclays boosted their target price on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 15th. Eighteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $252.48.

Johnson & Johnson Stock Down 0.4%

Shares of JNJ stock opened at $221.64 on Friday. Johnson & Johnson has a 12 month low of $146.12 and a 12 month high of $251.71. The company has a 50 day simple moving average of $237.59 and a two-hundred day simple moving average of $220.58. The stock has a market cap of $533.52 billion, a P/E ratio of 25.62, a P/E/G ratio of 2.20 and a beta of 0.27. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is currently 60.12%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,251,310.02. This trade represents a 4.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 30,142 shares of company stock valued at $7,360,528 in the last three months. Corporate insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. Blueline Advisors LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $25,000. Abich Financial Wealth Management LLC purchased a new stake in Johnson & Johnson during the 3rd quarter worth approximately $26,000. Cresta Advisors Ltd. bought a new position in Johnson & Johnson during the 4th quarter valued at $26,000. DecisionPoint Financial LLC grew its holdings in Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after acquiring an additional 75 shares in the last quarter. Finally, Family CFO Inc acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.